ebov

SP187 (MON-DNJ) is a host-targeted iminosugar. It has anti-filovirus infection activity.SP187 is used for therapeutic use against influenza and dengue viruses.

FGI-106 tetrahydrochloride demonstrates potent inhibitory activity across a broad spectrum of viruses, including those causing hemorrhagic fevers such as Ebola, Rift Valley, and Dengue Fever, with half-maximal effective concentrations (EC50s) of 100 nM, 800 nM, and 400-900 nM, respectively. Additionally, it effectively inhibits non-hemorrhagic fever viruses, notably HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively, indicating its broad-spectrum antiviral potential.

EBOV-IN-1 is an adamantane dipeptide piperazine inhibitor against Ebola virus (EBOV) that inhibits EBOV infection and suppresses pseudotypic EBOV infection.

EBOV-IN-10 is an orally active inhibitor of the Ebola virus (EBOV) with an EC50 value of 0.19 μM.

EBOVentry-IN-1 (compound Hu7) is an inhibitor of EBOV virus entry, with an IC50 of 1.50 μM.

EBOV-IN-2 (Compound 2) is an inhibitor of the Ebola virus (EBOV), with IC50 values of 0.37 μM for Ebola virus glycoprotein pseudotyped virus (pEBOV) and 2.54 μM for African Swine Fever Virus (ASFV).

EBOV-IN-6 (compound 19) is a benzothiazole compound. It demonstrates antiviral activity against pEBOV, with an IC50 value of 10 μM.

EBOV-IN-9 (compound 2b) is a Diphyllin derivative that inhibits Ebola virus entry with an EC50 of 40 nM. It effectively combats EBOV-infected monocyte-derived macrophages, showing an EC50 of 107 nM.

EBOVentry-IN-2 (compound 16) is an inhibitor of EBOV entry with an EC50 value of 4.42 μM and demonstrates metabolic stability.

EBOV-GP-IN-1 (Compound 28) is a potent inhibitor of Ebola virus entry, targeting the Ebola virus envelope glycoprotein (EBOV-GP) with an IC50 of 0.05 μM.

EBOV-IN-C31 is a novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties.

EBOV-IN-8 (Compound 30) effectively inhibits the Ebola pseudotyped virus (pEBOV) with an inhibition concentration (IC 50) of 62.1% at a dosage of 10 μM [1].

EBOV-IN-3 (compound 9), a benzothiazepine compound, and EBOV-IN-6 exhibit notable anti-pEBOV activity, with the latter demonstrating an IC 50 value of 0.37 μM [1].

EBOV-IN-4 (compound 12), a benzothiazepine, acts as a potent inhibitor against the Ebola virus (EBOV), displaying 64.9% inhibitory activity against EBOV-GP-pseudotype virus (pEBOV) at a concentration of 10 μM. It is, however, inactive against ASFV [1].

EBOV-IN-5 (compound 14) serves as an antiviral agent targeting the Ebola virus (EBOV) by disrupting its entry mechanism into host cells. It specifically blocks the interaction between the EBOV glycoprotein EBOV-GPcl and the essential host receptor NPC1, which is crucial for the virus's fusion and entry into the cell. [7] [1]

EBOV-IN-7 (compound 26) acts as an inhibitor against the Ebola virus EBOV, displaying an IC 50 value of 2.04 μM against pEBOV (EBOV-GP pseudotyped virus). It also obstructs the EBOV-GPcl/NPC1 interaction and exhibits inhibitory effects on cancer cells. [8] [1]

FGI-106 is a potent, broad-spectrum inhibitor demonstrating activity against various viruses, including Ebola, Rift Valley Fever, and Dengue Fever, exhibiting EC50 values of 100 nM, 800 nM, and 400-900 nM, respectively. Furthermore, it effectively inhibits non-hemorrhagic fever viruses such as HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively.

R 59-022 (DKGI-I) is a diacylglycerol kinase (DGK) inhibitor and a 5-HT Receptor antagonist that blocks filovirus internalization in host cells. R 59-022 activates protein kinase C (PKC), inhibits intestinal smooth muscle contractility, and enhances O2- production induced by 1-oleoyl-2-acetylglycerol.

Retro-2 (2-{[(5-methyl-2-thienyl)methylene]amino}) is a plant toxin ricin inhibitor, itprotects HeLa cells against Ricin, Stx1 and Stx2, selectively blocks retrograde toxin trafficking at the early endosome-TGN (trans-Golgi network) interface.

Galanin (2-11) amide is a synthetic peptide fragment of the neuropeptide galanin and an agonist of the galanin-2 (GAL2) receptor (EC50= 9.32 nM in a fluorescence imaging plate reader assay).1It selectively binds to the GAL2receptor (IC50= 1.76 nM for the rat receptor) over the GAL1receptor (IC50= 879 nM for the human receptor) but does also bind to the GAL3receptor (Ki= 271 nM for the rat receptor).1,2Intracerebroventricular administration of galanin (2-11) amide (1 nmol/animal) decreases immobility in the forced swim test in rats.3It also reduces the hind paw mechanical pain threshold and increases the hind paw cold sensitivity threshold in rats.1

β-Casomorphin (1-5), amide, bovine is a peptide derived from bovine β-Casomorphin.

Nitric Oxide Synthase (599-613) Blocking Peptide, Bovine Endothelial Cell (Ac-Pro-Tyr-Asn-Ser-Ser-Pro-Arg-Pro-Glu-Gln-His-Lys-Ser-Tyr-Lys-Cys) is a peptide that inhibits the function of NOSs as a result it blocks the production of NO. Because of the invol

[Nle8,18,Tyr34]-pTH (3-34) amide (bovine) ([Nle8,18,Tyr34]bPTH (3-34) amide) serves as a competitive inhibitor of biological responses stimulated by parathyroid hormone (PTH) in vitro [1]. This compound is an analogue of PTH.

Melamine-Bov IgG is a hapten-carrier protein conjugate formed by coupling Melamine to bovine immunoglobulin (bovIgG). As a hapten, Melamine alone cannot induce an immune response and must be conjugated to a large molecular protein to become a complete antigen with immunogenicity. Melamine-Bov IgG may be supplied as a lyophilized powder or as a solution. The solution is prepared in 0.01 M TBS (pH 7.4) buffer.